Monthly CERA treatment maintains stable hemoglobin levels in routine clinical practice of peritoneal dialysis patients

Renal Failure

Volumn 35, Issue 3, 2013, Pages 314-319

  González, M Teresa ^a   Ramos, Rosa ^b   Vera, Manel ^c   Barbosa, Francesc ^d   Garcia, Carmen ^e   Garcia, Isabel ^f   González Segura, Carlota ^a   Cuxart, Marc ^f   Teixidó, Josep ^g   De La Cruz, Juan José ^h  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c H Clinic i Provincial   (Spain)

^d Service of Nephrology   (Spain)

^e HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^f Nephrology Department   (Spain)

^g Nephrology Department   (Spain)

^h UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Anemia; CERA; Hemoglobin; Methoxy polyethylene glycol epoetin beta; Peritoneal dialysis

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; FERRITIN; HEMOGLOBIN; IRON; TRANSFERRIN; ERYTHROPOIETIN; MACROGOL DERIVATIVE;

ADULT; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; AGED; CLINICAL TRIAL; COMPLICATION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANEMIA; ERYTHROPOIETIN; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84875022458     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2012.755903     Document Type: Article

References (26)

1. Li S, Foley RN, Collins AJ. Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int. 2004;65:1864-1869
2. Horl WH. Anemia and its treatment in peritoneal dialysis patients. Wien Klin Wochenschr. 2005;117(Suppl 6):69-72
3. Perlman RL, Finkelstein FO, Liu L, et al. Quality of life in chronic kidney disease (CKD): A cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis. 2005;45:658-666
4. Sulowicz W, Locatelli F, Ryckelynck JP, et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol. 2007;2:637-646
5. Macdougall IC. How to optimize anemia therapy in peritoneal dialysis patients. Contrib Nephrol. 2006;150:202-213
6. Levin NW, Fishbane S, Canedo FV, et al. Intravenous methoxy polyethylene glycol-epoetin beta for hemoglobin control in patients with chronic kidney disease who are on dialysis: A randomized noninferiority trial (MAXIMA). Lancet. 2007;370:1415-1421
7. Canaud B, Mingardi G, Braun J, et al. Intravenous C.E. R.A. maintains stable hemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: Results from STRIATA, a randomized phase III study. Nephrol Dial Transplant. 2008; 23:3654-3661
8. Macdougall IC. CERA (Continuous Erythropoietin Receptor Activator): A new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep. 2005;4:436-440
9. Locatelli F, Villa G, de Francisco AL, et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable hemoglobin in patients with CKD on dialysis: once monthly administration. Curr Med Res Opin. 2007;23:969-979
10. Macdougall IC, Robson R,Opatrna S, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2006;1:1211-1215
11. Carrera F, Lok CE, De FA, et al. Maintenance treatment of renal anaemia in hemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: A randomized comparative trial. Nephrol Dial Transplant. 2010;25:4009-4017
12. Weinreich T, Leistikow F, Hartmann HG, et al. Monthly continuous erythropoietin receptor activator treatment maintains stable hemoglobin levels in routine clinical management of hemodialysis patients. Hemodial Int. 2012;16(1):11-19
13. Dellanna F, Winkler RE, Bozkurt F, et al. Dosing strategies for conversion of hemodialysis patients from short-Acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: Experience from the MIRACEL study. Int J Clin Pract. 2011;65:64-72
14. Fliser D, Kleophas W, Dellanna F, et al. Evaluation of maintenance of stable hemoglobin levels in hemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: The MIRACEL study. Curr Med Res Opin. 2010;26:1083-1089
15. Chen CY, Hsu HJ, Lin YY, Wu MS. Subcutaneous continuous erythropoietin receptor activator conversion provides practical advantages and potential convenience for peritoneal dialysis patients. Perit Dial Int. 2011;31:592-597
16. Cano F, Alarcon C, Azocar M, et al. Continuous EPO receptor activator therapy of anemia in children under peritoneal dialysis. Pediatr Nephrol. 2011;26(8):1303-1310
17. Selby NM, Fonseca SA, Fluck RJ, Taal MW. Hemoglobin variability with epoetin beta and continuous erythropoietin receptor activator in patients on peritoneal dialysis. Perit Dial Int. 2012;32:177-182
18. Locatelli F, Aljama P, Canaud B, et al. Target hemoglobin to aim for with erythropoiesis-stimulating agents: A position statement by ERBP following publication of the trial to reduce cardiovascular events with aranesp therapy (TREAT) study. Nephrol Dial Transplant. 2010;25:2846-2850
19. Anon. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis. 2006;47:S11-S145
20. Lacson E Jr, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis. 2003;41:111-124
21. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesisstimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006;17:1181-1191
22. van der Putten K, van der Baan FH, Schellekens H, Gaillard CA. Hemoglobin variability in patients with chronic kidney disease in the Netherlands. Int J Artif Organs. 2009;32:787-793
23. Walker R, Pussell BA. Fluctuations in hemoglobin levels in hemodialysis, pre-dialysis and peritoneal dialysis patients receiving epoetin alpha or darbepoetin alpha. Nephrology (Carlton) ;14:689-695
24. Collins AJ, Brenner RM, Ofman JJ, et al. Epoetin alfa use in patients with ESRD: An analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis. 2005;46:481-488
25. MinutoloR,ZamboliP,ChiodiniP,etal.Conversionofdarbepoetin to low doses of CERA maintains hemoglobin levels in non-dialysis chronic kidney disease patients. Blood Purif. 2010;30:186-194
26. Pannier A, Jordan P, Dougherty FC, Bour F, Reigner B. Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfa. Curr Med Res Opin. 2007;23:3025-3032